Ascertaining Evidence and Strategies for Medical Treatment of Adolescents with Substance Use Disorders (SUD)-View Presentation

Video Transcription

Video Summary

The presentation, led by Dr. Gentile and various colleagues from Wright State University, addresses the medical treatment of adolescents with substance use disorders, focusing on evidence-based strategies and challenges in this domain. The discussion begins with an overview by Dr. Neetha Bhatt, emphasizing that a majority of substance users start in adolescence, highlighting the gap in medication-assisted treatment (MAT) for this group compared to adults. The presentation thoroughly examines common substances, including opioids, alcohol, and cannabis, exploring their prevalence among young users and discussing available treatments, whether FDA-approved or off-label, and their efficacy and risks.<br /><br />Key points include the importance of combining pharmacotherapy with psychosocial support, acknowledging limited research specifically targeting adolescents, and the necessity to adapt adult data for younger demographics. Panelists emphasize that while medications like buprenorphine and naltrexone are under-utilized in adolescents, these treatments can significantly reduce cravings and aid in long-term recovery. Case studies illustrate complex realities faced by adolescents, where supportive family involvement and stable environments play critical roles in recovery prospects. Additionally, discussions touch on the stigmatization and barriers in accessing treatment, the impact of peer influences, and the interplay between mental health and substance use disorders in adolescents.<br /><br />The session concludes with acknowledging the complex nature of treating substance use in young people, advocating for multi-disciplinary approaches, and the essential need for ongoing research and adaptive treatment plans to improve outcomes for affected adolescents.

Keywords

adolescents

substance use disorders

evidence-based strategies

medication-assisted treatment

opioids

pharmacotherapy

psychosocial support

buprenorphine

naltrexone

stigma

mental health